Showing results (121-130 of 11,527) with videos related to
Sort By:
Pageof 1,153
British Journal of Clinical Pharmacology|December 29, 2021
A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptinJinmiao Lu, Lu Wang, Sufeng Zhou, et al.British Journal of Clinical Pharmacology|December 29, 2021
Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patientsCharlotte D C C van der Heijden, Rob Ter Heine, Emma J Kooistra, et al.British Journal of Clinical Pharmacology|March 1, 1990
The effects of ibuprofen and indomethacin on renal function in the presence and absence of frusemide in healthy volunteers on a restricted sodium dietA P Passmore, S Copeland, G D JohnstonBritish Journal of Clinical Pharmacology|April 1, 1990
Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothersH Echizen, M Nakura, T Saotome, et al.British Journal of Clinical Pharmacology|August 16, 2011
Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer proteinMichael-Friedrich Boettcher, Roland Heinig, Carsten Schmeck, et al.British Journal of Clinical Pharmacology|August 19, 2011
Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypothesesCynthia M Nijenhuis, Peter G J ter Horst, Nienke van Rein, et al.British Journal of Clinical Pharmacology|September 13, 2011
Anti-platelet therapy: glycoprotein IIb-IIIa antagonistsDavid J SchneiderBritish Journal of Clinical Pharmacology|January 31, 2012
Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variantsR Preston Mason, Robert F Jacob, Ruslan Kubant, et al.British Journal of Clinical Pharmacology|January 31, 2012
Progression of motor and nonmotor features of Parkinson's disease and their response to treatmentThuy C Vu, John G Nutt, Nicholas H G HolfordBritish Journal of Clinical Pharmacology|February 3, 2012
Model-based treatment optimization of a novel VEGFR inhibitorRon J Keizer, Anubha Gupta, Robert Shumaker, et al.Pageof 1,153